lunes, 28 de febrero de 2011

NOVARTIS: Piden que deje ya de j...udicializar sobre patentes en India.

Novartis has been urged to drop its "persistent legal actions" in India regarding patent coverage for its anticancer drug Glivec and a challenge to the country's patent laws over fears the latter could hinder access to medicines.

In a letter to Novartis chairman Daniel Vasella, Health Action International and other non-governmental organisations (Berne Declaration, Third World Network and Knowledge Ecology International) have urged the Swiss major to put an end to its five-year legal battle concerning Glivec/Gleevec (imatininb), its chronic myeloid leukaemia treatment. The NGOs note that despite three consecutive patent refusals pronounced by the Indian justice authorities since 2006, Novartis, through an appeal to the Supreme Court in August 2009, is "insistent in its attempt to challenge the Indian patent law." The next hearing of the Glivec case is scheduled for April 19.


Ver tambien:

Roche / Novartis: No debo ir a Davos...No debo ir a Davos...No debo ir a Davos...

No hay comentarios: